Category: Oncology

Q&A with Dr. Juliane Nguyen: Exosome Profiling with miRNA and Biotech’s Next Breakthrough

Dr. Juliane Nguyen is a professor in the Department of Pharmaceutical Sciences at the University of Buffalo. Her Therapeutic Biomaterials Laboratory investigates using exosomes and other nanoscale carriers for the treatment of diseases including cancer and ischemic heart disease. NanoString...

The IO Revolution, Part 3 of 4: The Role of the Tumor in the Cancer Immunity Cycle

Part one of this four-part series looked at how host, tumor, and environmental factors shape tumor-immune system interactions. Part two further examined the role of the host, and in this blog, we consider the role of the tumor in the...

/ March 9, 2017

The IO Revolution, Part 2 of 4: The Role of the Host in the Cancer Immunity Cycle

Part one of this four-part series looked at how host, tumor, and environmental factors shape tumor-immune system interactions. In the next few blogs, we will consider how each of these sources of inter-patient heterogeneity has the potential to influence the...

/ January 12, 2017

Presidents, Rock Stars and Companion Diagnostics: 2016 Review of Immunotherapy

President Jimmy Carter announced this spring that he no longer needed treatments for the metastatic melanoma found in his brain–after treatment with pembrolizumab (Keytruda, Merck), his physicians could no longer detect the cancer. In 2016, high-profile success stories, the inclusion...

/ January 7, 2017

The IO Revolution, Part 1 of 4: Opportunities and Challenges

Immuno-oncology (IO) focuses on harnessing the tremendous power of the human immune system to detect and destroy cancer cells.

/ November 21, 2016